Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea

Abstract One recent study showed that atomoxetine-oxybutynin combination (AOC) use is effective in reducing obstructive sleep apnea (OSA) severity. We used a nationwide database to examine the association between AOC use and the risk of OSA incidence. This retrospective cohort study used Taiwan’s Na...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tien-Yu Chen, Chi-Hsiang Chung, Hsin-An Chang, Yu-Chen Kao, Shan-Yueh Chang, Terry B. J. Kuo, Cheryl C. H. Yang, Wu-Chien Chien, Nian-Sheng Tzeng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1f8740631d4e4f08a87ef20c37e8375a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1f8740631d4e4f08a87ef20c37e8375a
record_format	dspace
spelling	oai:doaj.org-article:1f8740631d4e4f08a87ef20c37e8375a2021-12-02T16:04:30ZLong-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea10.1038/s41598-021-91988-52045-2322https://doaj.org/article/1f8740631d4e4f08a87ef20c37e8375a2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91988-5https://doaj.org/toc/2045-2322Abstract One recent study showed that atomoxetine-oxybutynin combination (AOC) use is effective in reducing obstructive sleep apnea (OSA) severity. We used a nationwide database to examine the association between AOC use and the risk of OSA incidence. This retrospective cohort study used Taiwan’s National Health Insurance Research Database between the years 2000 and 2015. The patients who used atomoxetine or oxybutynin were included as an exposed cohort. The exposed and unexposed groups were selected in a ratio of 1:3 with sex, age, and index year matching. We used the multivariate Cox proportional regression model to evaluate the association between AOC use and the risk of an incident diagnosis of OSA. The incidence rates of OSA in the exposed cohort (N = 8940) and the unexposed cohort (N = 26,820), were 21.92 and 22.93 per 100,000 person-years, respectively. The adjusted hazard ratio of oxybutynin use only and AOC with a treatment duration of ≥ 366 days were 0.307 (95% CI 0.204–0.995, P = 0.045) and 0.299 (95% CI 0.102–0.933, P = 0.002), respectively. Long-term atomoxetine-oxybutynin combination therapy may be beneficial to reduce the risk of obstructive sleep apnea. Further studies to examine these mechanisms are warranted.Tien-Yu ChenChi-Hsiang ChungHsin-An ChangYu-Chen KaoShan-Yueh ChangTerry B. J. KuoCheryl C. H. YangWu-Chien ChienNian-Sheng TzengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tien-Yu Chen Chi-Hsiang Chung Hsin-An Chang Yu-Chen Kao Shan-Yueh Chang Terry B. J. Kuo Cheryl C. H. Yang Wu-Chien Chien Nian-Sheng Tzeng Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
description	Abstract One recent study showed that atomoxetine-oxybutynin combination (AOC) use is effective in reducing obstructive sleep apnea (OSA) severity. We used a nationwide database to examine the association between AOC use and the risk of OSA incidence. This retrospective cohort study used Taiwan’s National Health Insurance Research Database between the years 2000 and 2015. The patients who used atomoxetine or oxybutynin were included as an exposed cohort. The exposed and unexposed groups were selected in a ratio of 1:3 with sex, age, and index year matching. We used the multivariate Cox proportional regression model to evaluate the association between AOC use and the risk of an incident diagnosis of OSA. The incidence rates of OSA in the exposed cohort (N = 8940) and the unexposed cohort (N = 26,820), were 21.92 and 22.93 per 100,000 person-years, respectively. The adjusted hazard ratio of oxybutynin use only and AOC with a treatment duration of ≥ 366 days were 0.307 (95% CI 0.204–0.995, P = 0.045) and 0.299 (95% CI 0.102–0.933, P = 0.002), respectively. Long-term atomoxetine-oxybutynin combination therapy may be beneficial to reduce the risk of obstructive sleep apnea. Further studies to examine these mechanisms are warranted.
format	article
author	Tien-Yu Chen Chi-Hsiang Chung Hsin-An Chang Yu-Chen Kao Shan-Yueh Chang Terry B. J. Kuo Cheryl C. H. Yang Wu-Chien Chien Nian-Sheng Tzeng
author_facet	Tien-Yu Chen Chi-Hsiang Chung Hsin-An Chang Yu-Chen Kao Shan-Yueh Chang Terry B. J. Kuo Cheryl C. H. Yang Wu-Chien Chien Nian-Sheng Tzeng
author_sort	Tien-Yu Chen
title	Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
title_short	Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
title_full	Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
title_fullStr	Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
title_full_unstemmed	Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
title_sort	long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1f8740631d4e4f08a87ef20c37e8375a
work_keys_str_mv	AT tienyuchen longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT chihsiangchung longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT hsinanchang longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT yuchenkao longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT shanyuehchang longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT terrybjkuo longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT cherylchyang longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT wuchienchien longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea AT nianshengtzeng longtermatomoxetineoxybutynincombinationusemaybebeneficialforthepreventionofobstructivesleepapnea
_version_	1718385195426512896

Long-term atomoxetine-oxybutynin combination use may be beneficial for the prevention of obstructive sleep apnea

Ejemplares similares